SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 235 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.09 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,542,391 | -8.8% | 346,115 | -0.5% | 0.12% | -0.8% |
| Q2 2023 | $10,457,423 | -18.0% | 347,885 | -1.2% | 0.12% | -21.7% |
| Q1 2023 | $12,753,286 | -2.0% | 352,009 | -3.5% | 0.15% | -6.2% |
| Q4 2022 | $13,008,813 | +2.5% | 364,699 | -2.7% | 0.16% | -5.3% |
| Q3 2022 | $12,690,000 | +14.6% | 374,901 | -2.0% | 0.17% | +20.4% |
| Q2 2022 | $11,069,000 | -6.5% | 382,744 | +4.5% | 0.14% | +12.7% |
| Q1 2022 | $11,839,000 | +9.0% | 366,292 | -1.7% | 0.13% | +14.5% |
| Q4 2021 | $10,862,000 | +8.5% | 372,509 | -0.8% | 0.11% | +11.1% |
| Q3 2021 | $10,010,000 | +2.8% | 375,332 | +18.7% | 0.10% | +3.1% |
| Q2 2021 | $9,739,000 | +6.0% | 316,301 | -9.8% | 0.10% | 0.0% |
| Q1 2021 | $9,184,000 | +2.5% | 350,784 | -1.5% | 0.10% | -5.9% |
| Q4 2020 | $8,963,000 | +20.0% | 356,225 | -0.6% | 0.10% | +2.0% |
| Q3 2020 | $7,470,000 | -17.7% | 358,466 | -6.2% | 0.10% | -21.9% |
| Q2 2020 | $9,080,000 | +49.4% | 382,296 | +13.1% | 0.13% | +25.5% |
| Q1 2020 | $6,079,000 | -35.5% | 337,935 | -14.9% | 0.10% | -15.0% |
| Q4 2019 | $9,418,000 | -12.6% | 397,029 | +1.3% | 0.12% | -20.0% |
| Q3 2019 | $10,775,000 | -15.2% | 392,090 | +2.1% | 0.15% | -16.7% |
| Q2 2019 | $12,707,000 | -13.8% | 384,017 | -8.7% | 0.18% | -15.9% |
| Q1 2019 | $14,745,000 | +6.7% | 420,799 | +1.2% | 0.21% | -6.1% |
| Q4 2018 | $13,819,000 | -24.0% | 415,993 | +15.1% | 0.23% | -11.6% |
| Q3 2018 | $18,193,000 | -1.8% | 361,332 | +16.7% | 0.26% | -6.5% |
| Q2 2018 | $18,527,000 | +3.9% | 309,556 | -20.5% | 0.28% | +0.4% |
| Q1 2018 | $17,829,000 | +14.6% | 389,271 | -0.3% | 0.28% | +16.0% |
| Q4 2017 | $15,555,000 | -3.4% | 390,343 | -3.0% | 0.24% | -10.2% |
| Q3 2017 | $16,103,000 | -11.5% | 402,565 | -4.6% | 0.26% | -15.9% |
| Q2 2017 | $18,195,000 | +23.9% | 422,168 | -10.0% | 0.31% | +20.8% |
| Q1 2017 | $14,681,000 | +29.9% | 469,044 | +4.8% | 0.26% | +22.1% |
| Q4 2016 | $11,301,000 | -7.2% | 447,549 | -9.1% | 0.21% | -12.7% |
| Q3 2016 | $12,174,000 | +9.3% | 492,274 | -10.0% | 0.24% | +3.0% |
| Q2 2016 | $11,143,000 | +35.9% | 547,018 | +1.8% | 0.24% | +30.2% |
| Q1 2016 | $8,198,000 | +13.1% | 537,593 | -0.3% | 0.18% | +11.7% |
| Q4 2015 | $7,247,000 | -9.1% | 539,228 | -5.1% | 0.16% | -13.8% |
| Q3 2015 | $7,974,000 | -25.5% | 568,351 | -9.8% | 0.19% | -19.2% |
| Q2 2015 | $10,697,000 | +22.4% | 629,951 | -12.9% | 0.23% | +23.2% |
| Q1 2015 | $8,741,000 | +38.3% | 722,991 | -5.1% | 0.19% | +33.8% |
| Q4 2014 | $6,322,000 | -1.8% | 761,715 | +2.8% | 0.14% | -7.8% |
| Q3 2014 | $6,437,000 | -27.2% | 740,753 | -8.3% | 0.15% | -25.6% |
| Q2 2014 | $8,843,000 | -6.0% | 807,563 | -23.2% | 0.21% | -8.8% |
| Q1 2014 | $9,406,000 | +18.6% | 1,052,150 | 0.0% | 0.23% | +17.0% |
| Q4 2013 | $7,933,000 | +63.2% | 1,052,150 | +58.6% | 0.19% | +45.9% |
| Q3 2013 | $4,862,000 | +49.8% | 663,357 | +31.4% | 0.13% | +38.5% |
| Q2 2013 | $3,245,000 | – | 504,647 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HealthInvest Partners AB | 335,000 | $8,934,000 | 13.38% |
| ASHFORD CAPITAL MANAGEMENT INC | 1,016,665 | $27,114,000 | 2.46% |
| Bruce & Co., Inc. | 402,105 | $10,724,000 | 2.28% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 297,500 | $7,934,000 | 1.91% |
| ARMISTICE CAPITAL, LLC | 3,900,000 | $104,013,000 | 1.76% |
| Bridge City Capital, LLC | 108,884 | $2,904,000 | 1.32% |
| S&T BANK/PA | 316,098 | $8,430,000 | 1.31% |
| Kent Lake Capital LLC | 100,000 | $2,667,000 | 1.15% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 331,140 | $8,832,000 | 1.02% |
| Prairiewood Capital, LLC | 45,297 | $1,208,000 | 0.99% |